Compare GSK plc (GSK) vs PubMatic Inc (PUBM) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

PUBM stock trades at $13.62, down 0.51% on the day, with a mixed technical picture showing a bullish moving average signal but a neutral oscillator stance. The company reported a net loss of -$14.46M for 2025 despite beating EPS estimates in recent quarters, with revenue of $282.93M. Positive news includes new product launches like AgenticOS and a Creator Marketplace, alongside a balanced analyst consensus of 8 Buy and 8 Hold ratings.

The outlook is cautiously optimistic, supported by strong operating cash flow of $81.06M and a consensus price target of $17.00, implying potential upside. Key risks include sustained negative profit margins and competitive pressures in the ad tech sector. Investor sentiment is buoyed by recent strategic partnerships and AI-driven growth initiatives, though profitability remains a critical watchpoint.